Compounds > amprenavir
Page last updated: 2024-08-24

amprenavir and HIV

amprenavir has been researched along with HIV in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (16.00)18.2507
2000's19 (76.00)29.6817
2010's1 (4.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Anderson, PS; Bacheler, LT; Chang, CH; Cordova, B; Erickson-Viitanen, S; Garber, S; Johnson, BL; Klabe, RM; Ko, SS; Lam, PY; Li, R; Reid, C; Rodgers, JD; Ru, Y; Seitz, SP; Trainor, GL; Wang, H; Wright, MR1
Furfine, ES; Hanlon, MH; Hazen, RJ; Miller, JF; Ray, JA; Robinson, L; Samano, V; Spaltenstein, A1
Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A1
Agniswamy, J; Ghosh, AK; Hattori, SI; Jadhav, RD; Kovela, S; Mitsuya, H; Osswald, H; Simpson, H; Wang, YF; Weber, IT1
Boucher, MJ; Brynda, J; Craik, CS; Drąg, M; Grzymska, J; Hájek, M; Hradilek, M; Konvalinka, J; Kryštůfek, R; Madhani, HD; Majer, P; Řezáčová, P; Rut, W; Šácha, P; Starková, J; Tloušt'ová, E1
Hidalgo Tenorio, C; Pasquau Liaño, J1
Bogner, JR; Eberle, J; Goebel, FD; Troendle, U1
Korn, K; Moschik, G; Paatz, C; Schmidt, B; Schnell, T; Thein, C; Walter, H1
Bates, M; Hellmann, N; Huang, W; Petropoulos, C; Wrin, T1
Chou, S; Marousek, GI; Murphy, MD1
Boeri, E; Castagna, A; Danise, A; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Seminari, E1
DeGoey, DA; Randolph, JT1
Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M1
De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Seminari, E; Soldarini, A; Spagnuolo, V; Uberti-Foppa, C1
de Béthune, MP; De Meyer, S; Picchio, G1
Bilello, JA; Drusano, GL1
Levin, J1
Chang, HE1
Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L1
Clavel, F; Damond, F; Descamps, D; Duval, X; Lamotte, C; Leport, C; Peytavin, G; Race, E; Vilde, JL1
Solignac, M1
Corral, A; de Mendoza, C; Gallego, O; Soriano, V1

Reviews

5 review(s) available for amprenavir and HIV

ArticleYear
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 10

    Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides

2008
Practical applications of viral fitness in clinical practice.
    Current opinion in infectious diseases, 2003, Volume: 16, Issue:1

    Topics: Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Mutation; Sulfonamides; Viral Load; Virus Replication

2003
Peptidomimetic inhibitors of HIV protease.
    Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane

2004
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
    AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1

    Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome

2008
[Resistance to protease inhibitors].
    Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:Monografic

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2001

Trials

1 trial(s) available for amprenavir and HIV

ArticleYear
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
    European journal of medical research, 2003, Feb-21, Volume: 8, Issue:2

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Viremia

2003

Other Studies

19 other study(ies) available for amprenavir and HIV

ArticleYear
Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Chemistry & biology, 1998, Volume: 5, Issue:10

    Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Dogs; Drug Design; HIV; HIV Protease Inhibitors; Molecular Structure; Mutation; Protein Binding; Urea; Virus Replication

1998
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Bioorganic & medicinal chemistry letters, 2004, Feb-23, Volume: 14, Issue:4

    Topics: Animals; Anti-HIV Agents; Cell Line; Drug Resistance, Multiple, Viral; HIV; HIV Protease; HIV Protease Inhibitors; Humans; Molecular Structure; Mutation; Rats; Structure-Activity Relationship; Sulfonamides

2004
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Bioorganic & medicinal chemistry letters, 2005, Aug-01, Volume: 15, Issue:15

    Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication

2005
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
    European journal of medicinal chemistry, 2018, Dec-05, Volume: 160

    Topics: Antiviral Agents; Chromans; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Protease; HIV Protease Inhibitors; Ligands; Models, Molecular; Molecular Structure; Naphthalenes; Structure-Activity Relationship

2018
Re-emerging Aspartic Protease Targets: Examining
    Journal of medicinal chemistry, 2021, 05-27, Volume: 64, Issue:10

    Topics: Antifungal Agents; Aspartic Acid Proteases; Binding Sites; Catalytic Domain; Cryptococcus neoformans; Crystallography, X-Ray; Drug Evaluation, Preclinical; Fungal Proteins; Fungi; HIV; HIV Protease; Molecular Dynamics Simulation; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity

2021
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Sulfonamides

2003
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 30, Issue:1

    Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Mutation; Mutation, Missense; Phenotype; Retrospective Studies; Salvage Therapy; Sulfonamides; Viral Load

2004
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides

2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Journal of medical virology, 2004, Volume: 74, Issue:1

    Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation, Missense; Ritonavir; Selection, Genetic; Sulfonamides; Treatment Failure; Viral Load; Viremia

2004
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
    The new microbiologica, 2007, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome

2007
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
    The Journal of infectious diseases, 1996, Volume: 173, Issue:6

    Topics: Antiviral Agents; Blood Proteins; Carbamates; Clinical Trials as Topic; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Orosomucoid; Protein Binding; Sulfonamides

1996
[Second chance therapy. New protease inhibitor for salvage therapy].
    MMW Fortschritte der Medizin, 2000, Mar-13, Volume: 142 Suppl 1

    Topics: Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Salvage Therapy; Sulfonamides; Treatment Outcome

2000
New protease drug shows early promise.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1995

    Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV; HIV Protease Inhibitors; Humans; Sulfonamides

1995
Conference looks at HIV drug resistance.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:9

    Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine

1995
[Determining resistance in HIV therapy. Careful interpretation only].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Resistance, Microbial; Furans; HIV; HIV Infections; Humans; Mutation; Sulfonamides

2001
Amprenavir (Agenerase).
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Practice Guidelines as Topic; Sulfonamides

2000
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; Humans; Ritonavir; RNA, Viral; Sulfonamides

2002
[Advances in the domain of HIV].
    Presse medicale (Paris, France : 1983), 2002, Jan-19, Volume: 31, Issue:2

    Topics: Anti-HIV Agents; Blood; Carbamates; Cerebrospinal Fluid; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genitalia; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Mutation; Phenotype; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; Sulfonamides; Time Factors; Viral Load

2002
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, May-01, Volume: 34, Issue:9

    Topics: Amino Acid Substitution; Anti-HIV Agents; Asparagine; Carbamates; Drug Hypersensitivity; Furans; Gene Frequency; HIV; HIV Protease; Humans; Mutation; Serine; Sulfonamides

2002